LabReady

Houston medical device startup enters clinical trials

LabReady ensures samples make it from the patient to the lab without compromising the quality of the sample. Photo via vaximmune.com

Houston-based Vax-Immune Diagnostics has commenced on a new multicenter clinical trial to roll out a specific lab test as a part of its LabReady product.

The 12-week study will analyze results from Group B Streptococcus lab tests in expecting mothers. Currently, 16 to 20 percent of pregnant women are affected by GBS, according to a news release, which will then infect their newborn through the childbirth process.

Vax-Immune's product, LabReady, enhances the transportation process of lab samples and aims to improve the quality of results in patients. The company is expected to report data from the trial this summer.

"Currently samples are not regulated through transport from the patient to the lab often causing inaccurate test results. And inaccurate test results can cause significant problems since medical decisions are based on these results," Dr. Leonard E. Weisman, president and chief technology officer at Vax-Immune Diagnostics, says in the release.

"Our device, LabReady collects, protects, processes, and prepares the sample from the patient through transport, so when it arrives at the laboratory, infection can easily and accurately be diagnosed."

This study is planned to randomize approximately 300 patients from 35 to 37 weeks of pregnancy, according to the release. GBS is the most common cause of infections such as sepsis, meningitis, and pneumonia among newborns. The Centers for Disease Control and Prevention, among other organizations, have launched efforts for screenings and tests to reduce cases of neonatal GBS disease.

Vax-Immune was a member of the Texas Medical Center's 2018 TMCx Medical Device cohort and pitched at the 7th TMCx Demo Day. The company is a JLABS @ TMC resident.

Hyundai has revealed the 11 hospitals that are receiving donations — and a Houston hospital made the list. Photo by Getty Images

As major corporations continue to react to the COVID-19 pandemic with relief and aid efforts, one automaker has decided to help fund testing in 11 children's hospital — and Houston-based Texas Children's Hospital has been named a beneficiary of the donation.

Last week, Hyundai Hope On Wheels and Hyundai Motor America announced that they were donating $2 million to 10 hospitals across the U.S. to aid with the operation of drive-thru coronavirus testing centers. This week, the two revealed that they upped the commitment, now offering help to 11 children's hospitals totaling $2.2 million.

"The Hyundai COVID-19 Drive-thru testing grants are designed to get urgent financial support to institutions on the front-line in the fight against the coronavirus" says José Muñoz, president and CEO of Hyundai Motor North America. "Children who are diagnosed with cancer are particularly at higher risk. That's why it was important to us to join forces with several children's hospitals around the nation to company this threat to the health and well-being of children. We are pleased to expand to 11 institutions nationwide, each with a $200,000 grant."

The other 10 hospitals receiving Hyundai COVID-19 Drive-Thru Testing grants are:

  • The Hyundai Cancer Institute at CHOC Children's, Orange, CA
  • UH Rainbow Babies and Children's, Cleveland, OH
  • Children's National Hospital, Washington, D.C.
  • Dana Farber / Boston Children's Hospital, Boston, MA
  • Seattle Children's Hospital, Seattle, WA
  • Columbia Medical Center, New York, NY
  • Joseph's Children's Hospital, Tampa, FL
  • Children's Hospital of Colorado, Aurora, CO
  • Children's Hospital of Philadelphia, Philadelphia, PA
  • University of Alabama Children's, Birmingham, AL

The Centers for Disease Control has built a website that offers resources to individuals who have questions about COVID-19, including how to identify symptoms, get tested, and decontaminate your home at www.cdc.gov.

------

This article originally ran on AutomotiveMap.